

17 October 2024

**Physiomics plc**  
**("Physiomics" or the "Company")**

**Notice of AGM**

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to provide notice of the Company's Annual General Meeting ("AGM").

The AGM will be held at 10.30 a.m. on 19 November 2024 at the Company's registered office, Bee House, 140 Eastern Avenue, Milton Park, Oxfordshire, OX14 4SB.

Shareholders will shortly be sent either printed copies of the Notice of AGM and accompanying materials or a letter notifying them that they are available on the Company's website, depending on the preferences they have expressed to the Company's registrar.

A copy of the Notice of AGM, containing further details of the resolutions to be proposed at the meeting, as well as a copy of the Company's Annual Report and Accounts, will be made available today on the Company's website at [www.physiomics.co.uk/investors/corporate-documents/](http://www.physiomics.co.uk/investors/corporate-documents/).

**Enquiries:**

**Physiomics plc**  
Dr Peter Sargent, CEO  
+44 (0)1235 841575

**Hybridan LLP (Broker)**  
Claire Louise Noyce  
+44 (0) 203 764 2341

**Strand Hanson Limited (NOMAD)**  
James Dance & James Bellman  
+44 (0)20 7409 3494

**Notes to Editor**

**About Physiomics**

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAGZMMGMVDGDZM